6-溴-N-甲基咪唑并[1,2-a]吡嗪-8-胺 | 117718-85-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 中文名称: 6-溴-N-甲基咪唑并[1,2-a]吡嗪-8-胺
• 英文名称: 6-bromo-8-(methylamino)imidazo<1,2-α>pyrazine
• 英文别名: (6-bromo-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine；6-bromo-N-methylimidazo[1,2-a]pyrazin-8-amine
• CAS: 117718-85-1
• 化学式: C₇H₇BrN₄
• 分子量: 227.063
• InChiKey: DGYNAGYJCRNBFI-UHFFFAOYSA-N

物化性质

• 密度：
  1.81±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  6-溴-N-甲基咪唑并[1,2-a]吡嗪-8-胺 在 palladium on activated charcoal 氢气 作用下， 生成 imidazo[1,2-a]pyrazin-8-yl-methyl-amine
  参考文献：
  名称：

  Synthesis and antibronchospastic activity of 8-alkoxy- and 8-(alkylamino)imidazo[1,2-a]pyrazines

  摘要：

  Theophylline still occupies a dominant place in asthma therapy. Unfortunatly its adverse central nervous system (CNS) stimulant effects can dramatically limit its use, and adjustments in the dosage are often needed. We have synthesized a new series of imidazo[1,2-a]pyrazine derivatives which are much more potent bronchodilators than theophylline in vivo and do not exhibit the CNS stimulatory profile. In vitro studies on isolated rat uterus and guinea pig trachea confirm the high potentialities of these derivatives. 6-Bromo-8-(methylamino)imidazo[1,2-a]pyrazine-3-carbonitrile (23) is identified as the most potent compound of the series. As in the case of theophylline, phosphodiesterase inhibition appears unlikely to be the unique mechanism of action of this series of heterocycles.

  DOI：

  10.1021/jm00096a008
• 作为产物：
  描述：

  6,8-二溴咪唑并[1,2-a]吡嗪 、 甲胺 以 水 为溶剂， 反应 24.0h， 生成 6-溴-N-甲基咪唑并[1,2-a]吡嗪-8-胺
  参考文献：
  名称：

  [EN] 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  [FR] 6-ARYKL-IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES, PROCEDE DE PREPARATION ET PROCEDE D'UTILISATION CORRESPONDANTS

  摘要：

  一种组合物包括公式（I）的化合物，其药用盐、水合物、溶剂合物、晶型、对映体、前药或其混合物。该组合物在治疗激酶相关疾病方面具有特殊的效用。

  公开号：

  WO2004022562A1

文献信息

• Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
  申请人：Sun Li Connie

  公开号：US20050009832A1

  公开（公告）日：2005-01-13

  The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

  本发明涉及8-氨基-芳基取代的咪唑并吡嗪类化合物，这些化合物能够调节蛋白激酶（“PKs”）的活性。因此，本发明的化合物可用于治疗与异常PK活性相关的疾病。本发明还公开了包含这些化合物的药物组合物、使用包含这些化合物的药物组合物治疗疾病的方法以及它们的制备方法。
• Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors
  申请人：Sugen, Inc.

  公开号：US20040220189A1

  公开（公告）日：2004-11-04

  The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

  本发明涉及调节蛋白激酶（“PKs”）活性的8-氨基芳基取代咪唑吡嘧啶化合物。因此，本发明的化合物在治疗与异常PK活性相关的疾病方面是有用的。还公开了包含这些化合物的药物组合物、利用包含这些化合物的药物组合物治疗疾病的方法以及它们的制备方法。
• Nitration in the imidazo[1,2-<i>a</i>]pyrazine series. Experimental and computational results
  作者：Olivier Vitse、Pierre-Antoine Bonnet、Jacques Bompart、Henri Viols、Guy Subra、Jean-Pierre Chapat、Gérard Grassy

  DOI：10.1002/jhet.5570340301

  日期：1997.5

  Nitration was carried out on a series of imidazo[1,2-a]pyrazine derivatives. The reactivities of diversely substituted derivatives and of all positions of substitution were analysed and experimental results compared with 13-nmr data and semi empirical calculations (AMI). Although the unsubstituted heterocycle is highly resistant to nitration, electron-donating groups such as alkoxy or alkylamino on

  在一系列咪唑并[1,2- a ]吡嗪衍生物上进行硝化。分析了不同取代的衍生物和所有取代位置的反应性，并将实验结果与13 nmr数据和半经验计算（AMI）进行了比较。尽管未取代的杂环对硝化具有很高的抵抗力，但供电子基团，例如8位上的烷氧基或烷基氨基，可增强咪唑并[1,2- a ]吡嗪衍生物对亲电取代，特别是硝化的反应性。在13-nmr实验，电子分布和以中性形式计算的分子静电势等密度面与实验结果非常吻合，表明位置3是硝化反应中最活泼的位置。
• PYRIDINONYL PDK1 INHIBITORS
  申请人：Lind Kenneth Egnard

  公开号：US20100144730A1

  公开（公告）日：2010-06-10

  The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.

  本发明提供了吡啶基PDK1抑制剂及其使用方法，用于治疗癌症。
• HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR
  申请人：Hangzhou Innogate Pharma Co., Ltd.

  公开号：EP3553065A1

  公开（公告）日：2019-10-16

  A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof. Specifically, the present invention relates to a compound of formula (I), the compound having dual inhibitory activity for Syk and/or Syk-HDAC.

  一种作为 Syk 抑制剂和/或 Syk-HDAC 双重抑制剂的杂环化合物，或其药学上可接受的盐、原药、氘代衍生物、水合物和溶液。具体而言，本发明涉及一种式（I）化合物，该化合物对 Syk 和/或 Syk-HDAC 具有双重抑制活性。